|本期目录/Table of Contents|

[1]宫 帅,任 敏,秦 克.乌美溴铵维兰特罗对AECOPD患者的临床分析[J].中华肺部疾病杂志,2022,(02):240-242.[doi:10.3877/cma.j.issn.1674-6902.2022.02.026]
点击复制

乌美溴铵维兰特罗对AECOPD患者的临床分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2022年02期
页码:
240-242
栏目:
临床研究
出版日期:
2022-04-20

文章信息/Info

Title:
-
作者:
宫 帅1; 任 敏2; 秦 克1
610041 成都,西南医科大学附属成都363医院呼吸与危重医学科1 610000 成都,四川省医学科学院四川省人民医院老年医学科2
Author(s):
-
关键词:
急性加重期; 肺疾病; 慢性阻塞性;  乌美溴铵维兰特罗;  安全性;  临床分析
Keywords:
-
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2022.02.026
摘要:
目的 分析乌美溴铵维兰特罗对慢性阻塞性肺疾病急性加重期(AECOPD)患者的近远期疗效及安全性。方法 选择2018年10月至2019年10月我院收治的58例AECOPD患者分为对象,随机分为观察组31例,对照组27例。对照组患者吸入噻托溴铵粉雾剂,每次 18 μg,每天1次。观察组给予乌美溴铵维兰特罗吸入粉雾剂,每次吸入62.5 μg/25 μg,每天1次。持续治疗2周后观察效果并随访12个月。记录两组近远期疗效及药物安全性。结果 治疗前两组用力肺活量(FVC)、第一秒用力呼气容积(FEV1)水平对比差异均无统计学意义(P>0.05),治疗后两组FVC、FEV1均高于治疗前(P<0.05),治疗后观察组FVC、FEV1均高于对照组(P<0.05),12个月随访期间,两组本次急性加重的时间间隔分别为(135.80±21.35)d、(119.45±18.83)d,随访12个月内急性加重的次数分别为(1.79±0.31)次、(2.28±0.39)次,差异有统计学意义(P<0.05)。治疗期间,观察组药物不良反应发生率为12.90%,对照组不良反应发生率为11.11%,差异无统计学意义(P>0.05)。结论 乌美溴铵维兰特罗可改善AECOPD患者肺功能,增加疗效,安全性好。
Abstract:
-

参考文献/References:

1 Corlateanu A, Mendez Y, Wang Y, et al. Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art[J]. Pulmonology, 2020, 26(2): 95-100.
2 Halpin DMG, Criner GJ, Papi A, et al. The 2020 GOLD Science Committee Report on COVID-19 and chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2021, 203(1): 24-36.
3 Duffy SP, Criner GJ. Chronic obstructive pulmonary disease: evaluation and management[J]. Med Clin North Am, 2019, 103(3): 453-461.
4 Celli BR, Wedzicha JA. Update on clinical aspects of Chronic obstructive pulmonary disease[J]. N Engl J Med, 2019, 381(13): 1257-1266.
5 Bonnevie T, Elkins M. Chronic obstructive pulmonary disease[J]. J Physiother, 2020, 66(1): 3-4.
6 Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations[J]. Clin Chest Med, 2020, 41(3): 421-438.
7 Sorathia L. Palliative care in chronic obstructive pulmonary disease[J]. Med Clin North Am, 2019, 103(3): 517-526.
8 夏元旦, 杜晓梅, 周 敏, 等. 吸入型长效抗胆碱能药物及吸入型长效β2受体激动剂在慢性阻塞性肺疾病患者中的应用评价[J]. 药学服务与研究, 2019, 19(3): 56-58.
9 薛佩妮, 冯敏娟, 王惠琴. 噻托溴铵粉联合糖皮质激素治疗慢性阻塞性肺疾病疗效及对患者生活质量评分的影响[J]. 陕西医学杂志, 2020, 49(2): 216-219.
10 Albertson TE, Bowman WS, Harper RW, et al. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD[J]. Int J Chron Obstruct Pulmon Dis, 2019, 6(14): 1251-1265.
11 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等.慢性阻塞性肺疾病基层诊疗指南(实践版?2018)[J]. 中华全科医师杂志, 2018, 17(11): 871-877.
12 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊断指南[J]. 中华结核和呼吸杂志, 2013, 36(4): 255-264.
13 朱成华, 蔡 璐, 安伯萍, 等. 慢性阻塞性肺疾病伴认知功能障碍患者血清lipocalin-2表达及意义[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(1): 29-32.
14 Horodinschi RN, Bratu OG, Dediu GN, et al. Heart failure and chronic obstructive pulmonary disease: a review[J]. Acta Cardiol, 2020, 75(2): 97-104.
15 Sakao S. Chronic obstructive pulmonary disease and the early stage of cor pulmonale: A perspective in treatment with pulmonary arterial hypertension-approved drugs[J]. Respir Investig, 2019, 57(4): 325-329.
16 Wouters EF, Posthuma R, Koopman M, et al. An update on pulmonary rehabilitation techniques for patients with chronic obstructive pulmonary disease[J]. Expert Rev Respir Med, 2020, 14(2): 149-161.
17 任成山, 王关嵩, 钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
18 Guerreiro I, Soccal PM. COPD and phenotypes[J]. Rev Med Suisse, 2019, 15(671): 2082-2086.
19 Perez-Padilla R, Menezes AMB. Chronic obstructive pulmonary disease in latin America[J]. Ann Glob Health, 2019, 85(1): 7-10.
20 Cavallazzi R, Ramirez J. Community-acquired pneumonia in chronic obstructive pulmonary disease[J]. Curr Opin Infect Dis, 2020, 33(2): 173-181.
21 Li T, Gao L, Ma HX, et al. Clinical value of IL-13 and ECP in the serum and sputum of eosinophilic AECOPD patients[J]. Exp Biol Med(Maywood), 2020, 245(14): 1290-1298.
22 Cole JL, Smith S. Provider perceptions on steroid dosing in AECOPD:laying the groundwork for steroid stewardship[J]. Clin Respir J, 2020, 14(11): 1105-1108.
23 Di J, Li X, Xie Y, et al. Procalcitonin-guided antibiotic therapy in AECOPD patients: overview of systematic reviews[J]. Clin Respir J, 2021, 15(6): 579-594.
24 Qu F, Liu F, Zhang H, et al. Comparison of air pollutant-related hospitalization burden from AECOPD in Shijiazhuang, China, between heating and non-heating season[J]. Environ Sci Pollut Res Int, 2019, 26(30): 31225-31233.
25 Ferguson GT, Darken P, Ballal S, et al. Efficacy of budesonide/glycopyrronium/formoterol fumarate metered dose inhaler(BGF MDI)versus other inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist(ICS/LAMA/LABA)triple combinations in COPD: A systematic literature review and network meta-analysis[J]. Adv Ther, 2020, 37(6): 2956-2975.
26 Sliwka A, Jankowski M, Gross-Sondej I, et al. Once-daily long-acting beta2-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2018, 8(8): 1235-1237.
27 陈健聪, 吴锡平. 糠酸氟替卡松/维兰特罗治疗慢性阻塞性肺疾病的有效性与安全性[J]. 国际呼吸杂志, 2018, 38(7): 549-553.
28 户 光, 刘梓晗, 魏玉娜, 等. LABA/LAMA联合治疗中到极重度COPD有效性和安全性的网状Meta分析[J]. 药物流行病学杂志, 2020, 29(1): 6-18.

备注/Memo

备注/Memo:
通信作者: 任 敏, Email: 447077120@qq.com
更新日期/Last Update: 2022-04-20